Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T; Japan Adult Leukemia Study Group.
Miyazaki Y, et al. Among authors: chiba s.
Int J Hematol. 2022 Aug;116(2):228-238. doi: 10.1007/s12185-022-03347-3. Epub 2022 May 4.
Int J Hematol. 2022.
PMID: 35508695
Clinical Trial.